ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1173

Bringing Reproductive Health Guidelines into Fellowship Training: A National Survey of Adult and Pediatric Rheumatology Fellows and Program Directors to Assess Educational Need and Inform Curriculum Development
Abstract Number: 0035

Bromodomain Protein-regulated Stress Response in Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 1617

Burden of Adverse Childhood Experiences in Pediatric Chronic Pain and Rheumatic Disease
Abstract Number: 0367

Can Belonging to an AxSpA Patient Organization Be Associated with Benefits to Its Members? Results from the European Map of Axial Spondyloarthritis (EMAS)
Abstract Number: 1840

Can Dual-energy CT Lung Perfusion Detect Abnormalities at the Level of Lung Circulation in Systemic Sclerosis (SSc) ? Preliminary Experience in 101 Patients
Abstract Number: 0257

Can We Assess Disability in Juvenile Idiopathic Arthritis with Two Simple Questions? Results from the CAPRI Registry
Abstract Number: 0422

Cancer in Patients with ANCA-associated Vasculitis: Which Came First, the Chicken or the Egg?
Abstract Number: 1456

Cannabidiol Treatment in Hand Osteoarthritis and Psoriatic Arthritis – A Randomized, Double-blind Placebo-controlled Trial
Abstract Number: 0162

Cardiac Magnetic Resonance Imaging for Guiding Decision-making on Treatment Duration: Data from RHAPSODY, a Phase 3 Clinical Trial of Rilonacept in Recurrent Pericarditis
Abstract Number: 0083

Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome
Abstract Number: 1093

Cardiovascular and Lipid Biomarker Distributions in Inflammatory Arthritis
Abstract Number: 0286

Cardiovascular Disease Risk in Inflammatory Arthritis Patients Still Substantially Elevated in 2020
Abstract Number: 0679

Cardiovascular Risk Associated with Treatment of Allopurinol and Benzbromarone in Patients with Gout
Abstract Number: 0708

Cardiovascular Risk in Myositis Patients Compared to General Population – Preliminary Data from a Single-centre Cross-sectional Study
Abstract Number: 0283

Cardiovascular Risk Management in Patients with Rheumatoid Arthritis: A Single-centered Cross-sectional Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].